Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAccelerate Diagnostics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.54 | -$0.54 | -$0.54 |
| Q2 2024 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q3 2024 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q4 2024 | 1 | -$0.50 | -$0.50 | -$0.50 |
| Q1 2025 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q2 2025 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q3 2025 | 1 | -$0.50 | -$0.50 | -$0.50 |
| Q4 2025 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q1 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q2 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2026 | 1 | -$0.05 | -$0.05 | -$0.05 |
| Q4 2026 | 1 | -$0.11 | -$0.11 | -$0.11 |
Accelerate Diagnostics, Inc. Earnings Date And Information
Accelerate Diagnostics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.59 earnings per share for the quarter, missing analysts' consensus estimates of $-0.47 by $0.12. The company had revenue of 2.98 M for the quarter and had revenue of 12.06 M for the year. Accelerate Diagnostics, Inc. has generated $-5 earnings per share over the last year ($-4.94 diluted earnings per share) and currently has a price-to-earnings ratio of -0.52. Accelerate Diagnostics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Accelerate Diagnostics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.47 | -$0.59 | -0.12 | $3.03 M | $2.98 M |
| 08/08/2024 | Q2 2024 | -$0.55 | -$0.50 | 0.05 | $3.01 M | $2.99 M |
| 05/10/2024 | Q1 2024 | -$0.74 | $2.92 M | |||
| 03/28/2024 | Q4 2023 | -$0.89 | $3.00 M | |||
| 11/09/2023 | Q3 2023 | -$0.94 | $0.06 | 1 | $3.53 M | $3.30 M |
| 08/14/2023 | Q2 2023 | -$2.36 | $3.60 M | $2.92 M | ||
| 05/15/2023 | Q1 2023 | -$1.83 | $2.81 M | |||
| 03/31/2023 | Q4 2022 | -$1.52 | $2.97 M | |||
| 03/03/2023 | Q3 2022 | -$1.91 | $3.75 M | $2.96 M | ||
| 08/15/2022 | Q2 2022 | -$0.28 | -$2.31 | -2.03 | $3.00 M | $3.86 M |
| 05/16/2022 | Q1 2022 | -$3.20 | -$1.84 | 1.36 | $2.96 M | |
| 03/14/2022 | Q4 2021 | -$3.50 | $3.34 M | |||
| 11/15/2021 | Q3 2021 | -$1.47 | $3.61 M | $3.12 M | ||
| 08/10/2021 | Q2 2021 | -$3.55 | $3.06 M | $2.80 M | ||
| 05/07/2021 | Q1 2021 | -$4.14 | $2.52 M | |||
| 03/01/2021 | Q4 2020 | -$3.31 | $3.11 M | |||
| 11/06/2020 | Q3 2020 | -$3.32 | $3.27 M | $3.59 M | ||
| 08/07/2020 | Q2 2020 | -$3.47 | $2.47 M | $2.13 M | ||
| 05/08/2020 | Q1 2020 | -$3.89 | $2.34 M | |||
| 02/27/2020 | Q4 2019 | -$3.90 | $3.47 M |
Accelerate Diagnostics, Inc. Earnings: FAQ's
When is Accelerate Diagnostics, Inc.'s earnings date?
Accelerate Diagnostics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
How can I listen to Accelerate Diagnostics, Inc.'s earnings conference
call?
The conference call for Accelerate Diagnostics, Inc.'s latest earnings report can be listened to online.
How can I read Accelerate Diagnostics, Inc.'s conference call transcript?
The conference call transcript for Accelerate Diagnostics, Inc.'s latest earnings report can be read online.
How much revenue does Accelerate Diagnostics, Inc. generate each year?
Accelerate Diagnostics, Inc. (:AXDX) has a recorded annual revenue of $12.06 M.
How much profit does Accelerate Diagnostics, Inc. generate each year?
Accelerate Diagnostics, Inc. (:AXDX) has a recorded net income of $12.06 M. Accelerate Diagnostics, Inc. has generated $-4.94 earnings per share over the last four quarters.
What is Accelerate Diagnostics, Inc.'s price-to-earnings ratio?
Accelerate Diagnostics, Inc. (:AXDX) has a price-to-earnings ratio of -0.52 and price/earnings-to-growth ratio is 0.02.